UroStream

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai. With the deeper integration of targeted therapy and immunotherapy, survival outcomes for advanced renal cell carcinoma (RCC) continue to improve. Clinical attention has also shifted from “whether to combine treatments” toward “how to select the optimal combination, how to sequence subsequent therapies, and how to balance efficacy with safety.” Oncology Frontier – Urology Frontier invited Professor Guohai Shi of Fudan University Shanghai Cancer Center for an exclusive interview. Professor Shi shared his clinical perspectives on long-term benefit, first-line treatment selection, decision-making after disease progression, and whole-course management in the real-world setting.

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai. In recent years, innovative approaches including antibody-drug conjugates (ADCs), immunotherapy, and precision diagnostics have developed rapidly, shifting the treatment goals of urothelial carcinoma from short-term disease control toward deeper responses, long-term survival, and comprehensive disease management. Enfortumab vedotin-based combination therapy has changed the first-line treatment standard for locally advanced or metastatic urothelial carcinoma (LA/mUC). At the same time, patient selection, standardized treatment, adverse event management, response assessment, and long-term follow-up in real-world practice have become critical to translating evidence-based benefits into meaningful clinical outcomes. Oncology Frontier · UroStream invited Professor Dingwei Ye of Fudan University Shanghai Cancer Center to share his clinical perspectives on first-line treatment transformation, standardized continuous treatment, and advances in perioperative research.

Building on the evidence from the pivotal FRUSICA-2 registration study, the FRUSICA-2 Case Series has now been officially launched. This case collection brings together real-world clinical cases from multiple centers across China, providing practical insights into the clinical application of fruquintinib plus sintilimab as second-line treatment for advanced renal cell carcinoma. Scan the QR code to access the complete case collection.

In recent years, urology has entered an important period of rapid technological iteration and continuous evolution in treatment concepts. From the accelerated development of advanced domestically manufactured medical equipment to the growing integration of robotic-assisted surgery, molecular imaging, and artificial intelligence into clinical practice, urology is moving toward increasingly minimally invasive, precise, and function-preserving approaches. At the same time, high-quality clinical research has become an important foundation for updating treatment standards and strengthening China's academic influence in urology. Oncology Frontier – UroStream invited Professor Shaogang Wang of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, for an in-depth interview. He shared his perspectives on trends in urological development, the clinical value and technological advances of robotic-assisted surgery, and strategies for conducting high-quality clinical research.

The Pujiang Prostate Cancer Academic Conference was held in Shanghai on June 26–27, 2026. In recent years, the development of multiple innovative therapeutic approaches—including radioligand therapy, antibody-drug conjugates (ADCs), bispecific antibodies, and PARP inhibitors—has accelerated rapidly. A series of clinical studies has opened new treatment pathways for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). To systematically review the evolving landscape of prostate cancer treatment, Oncology Frontier – UroStream invited Professor Xiao Lin Lu of Fudan University Shanghai Cancer Center to share his insights.

The 2026 Pujiang Prostate Cancer Academic Conference was held in Shanghai from June 26–27, 2026. As treatment strategies for prostate cancer continue to evolve, local therapy has progressed beyond conventional radical surgery toward robot-assisted precision surgery with greater emphasis on functional preservation. Meanwhile, focal therapies such as cryoablation and irreversible electroporation (IRE) have emerged as promising treatment options for carefully selected patients.

The treatment landscape for advanced urothelial carcinoma (UC) has entered a new era. Antibody-drug conjugates (ADCs) targeting Nectin-4, HER2, and Trop-2 have rapidly transformed clinical practice, while ADCs combined with immune checkpoint inhibitors have become the new standard for first-line treatment. At the 2026 CSCO Annual Meeting, Prof. Kaiwei Yang from the Department of Urology, Peking University First Hospital presented a comprehensive overview of the current evidence supporting approved and investigational ADCs. Drawing on the latest 2026 CSCO Guidelines, he systematically reviewed first-line treatment strategies, sequencing after disease progression, breakthroughs in domestically developed ADCs, and the next generation of emerging targets, providing valuable insights into individualized treatment for advanced urothelial carcinoma.